NanoViricides Inc. (NNVC)

[changes_iv]

Dr. Seymour said, "...we are a company...with the ability to rapidly create drugs, and when I say rapidly create drugs I'm talking about weeks instead of years..."

"by the way, I'm sure that when you think human trials for drugs you think of hundreds of millions of dollars and years of time, well in this case because the disease only lasts a week, two weeks,...that it is possible to complete human trials in the space of a few short months...four parts to the human trials" ~ Dr. Eugene Seymour, CEO Nanoviricides, Inc.

In the following video, the coalition of people gathered are questioning why Gilead Sciences stopped Phase 3 of Sofosbuvir. I speculate it is because they have estimated, calculated probability, that they will not be able to recoup money in their investment if they were to continue. Competition is good and will be going to market on their heels as well.

This could easily be solved if the government regulatory agency give them green-light to market (approval). Gilead Sciences, Inc. is claiming 12 weeks will cure 90% of the subjects under their regimen. If toxicity data/information is very good let them prove efficacy in the marketplace. After all, it is the reputation of Gilead Sciences, Inc. that is on the line. If Gilead Sciences, Inc. were to fail and cause harm to the public they could become target of class action lawsuits.

The claim: "Current treatments can take up to a year of therapy and cure only about three out of four patients. Gilead’s daily pill can cure up to 90 percent of patients infected with the most common form of the virus in just 12 weeks."

I say it is up to the government to figure out if they can give approval now to Sofosbuvir or not. Regardless if Sofosbuvir gets approved soon or not, NanoViricides, Inc. will have HVC-Cide for the market, not far down the road, in a few weeks for "tox studies" followed by a few months for the clinical trials.